A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model - Summary - MDSpire

A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model

  • By

  • Leonie Bettin

  • Christine Unterweger

  • Maximiliane Dippel

  • Tamara Borysova

  • Maria Stadler

  • Jonathan Harris

  • James Rozzelle

  • Daisy Arroyo

  • Jeff Fairman

  • Taylor B. Poston

  • Eric Perouzel

  • Thierry Lioux

  • Juan F. Hernandez-Franco

  • Harm HogenEsch

  • Andrea Buzanich-Ladinig

  • Toni Darville

  • Tobias Käser

  • May 1, 2026

  • 0 min

Share

Objective:

To assess the immunogenicity of three specific vaccine candidates based on Chlamydial Protease-like Activity Factor (CPAF) in a porcine model.

Key Findings:
  • The CPAF-STG1151 conjugate generated the most potent systemic T cell reaction compared to other candidates.
  • A vigorous cell-mediated immune response was marked by IFNγ production, facilitated by all T cell subsets (CD4, CD8, and γδ T cells), regardless of the vaccine formulation.
  • The method of administration (IM vs. ID) did not significantly influence the immune response across the different vaccine candidates.
  • Highest anti-CPAF IgG serum concentrations were noted with the CPAF-STG1151 conjugate, indicating its superior immunogenicity.
Interpretation:

Linking the STING pathway activator STG1151 to CPAF resulted in a highly immunogenic subunit vaccine, indicating potential for effective Chlamydia trachomatis vaccination and paving the way for future clinical trials.

Limitations:
  • The study was conducted in a porcine model, which may not fully replicate human immune responses, necessitating further validation in human clinical trials.
  • Further investigations are needed to evaluate mucosal delivery methods and overall vaccine effectiveness in diverse populations.
Conclusion:

The CPAF-STG1151 conjugate vaccine shows promise as a candidate for Chlamydia trachomatis vaccination, warranting further research.

Original Source(s)

A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model

  • by Leonie Bettin, Christine Unterweger, Maximiliane Dippel, Tamara Borysova, Maria Stadler, Jonathan Harris, James Rozzelle, Daisy Arroyo, Jeff Fairman, Taylor B. Poston, Eric Perouzel, Thierry Lioux, Juan F. Hernandez-Franco, Harm HogenEsch, Andrea Buzanich-Ladinig, Toni Darville, Tobias Käser

  • May 1, 2026

Related Content

Distribution of HPV Genotypes and Epidemiological Insights in Northern Iran

Proportion of Anal and Penile Squamous Cell Carcinoma Linked to HPV: A Study Conducted in Specialized Hospitals in Sri Lanka

Human Papillomavirus Vaccine Discourse and Sentiment on Reddit Before and After COVID-19: Mixed Methods Retrospective Cross-Sectional Study